Recent therapeutic advances in oncology have been driven by the identification of tumour
genotype variations between patients, called interpatient heterogeneity, that predict the …

PURPOSE AND METHODS The expanding role of oral chemotherapy in oncology is
suggested by the abundance of orally formulated agents currently in development. The …

The National Cancer Institute (NCI) Investigational Drug Steering Committee (IDSC) charged
the Biomarker Task Force to develop recommendations to improve the decisions about …

Background Oncogenic fusion genes consisting of EML4 and anaplastic lymphoma kinase (ALK)
are present in a subgroup of non–small-cell lung cancers, representing 2 to 7% of such …

… Address reprint requests to Mark J. Ratain, MD, University of Chicago, 5841 S Maryland
Ave, MC2115, … The results of this placebo-controlled phase II study clearly demonstrate that …

Purpose Severe toxicity is commonly observed in cancer patients receiving irinotecan. UDP-glucuronosyltransferase
1A1 (UGT1A1) catalyzes the glucuronidation of the active …

Irinotecan (CPT-11) is a promising antitumor agent, recently approved for use in patients
with metastatic colorectal cancer. Its active metabolite, SN-38, is glucuronidated by hepatic …

BACKGROUND Cancer and its treatment lead to increased financial distress for patients. To
the authors' knowledge, to date, no standardized patient‐reported outcome measure has …

Purpose XL184 (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth
factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive …

Irinotecan (7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin (CPT-11) is
hydrolyzed by the enzyme carboxyl esterase to 7-ethyl-10-hydroxycamptothecin (SN-38), …